(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs PAC 1 (Primary) ; Temozolomide (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Acronyms Component 2
- Sponsors Vanquish Oncology
- 04 Jun 2019 Trial design of the study presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 03 Apr 2019 Results of STM-03 of component 1 (n=44) and component-2 (n=12) study presented at the 110th Annual Meeting of the American Association for Cancer Research.
- 07 Mar 2019 Planned End Date changed from 30 Jun 2019 to 30 Jun 2020.